The tumor suppressor Smad4/DPC4 is an essential transcription factor in the TGF-β pathway that was previously thought to function constitutively. We recently reported that Smad4 activity and stability are directly regulated by 2 major signaling pathways, RTK/MAPK and Wnt/GSK3. Here we examine the molecular, cellular, and potential therapeutic significance of these findings.
No takes yet. Share an insight, caveat, or question.
Demagny et al. (2015) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: